药物反应的个体差异一直存在于临床治疗中。参与药物吸收、分布、代谢和排泄（ADME）的基因在药代动力学过程中起着重要作用。遗传多态性和核受体对药物代谢酶和转运体表达的影响只能解释部分临床治疗中的个体差异。多个关键ADME基因已被证明可以通过表观遗传机制来调节，从而影响治疗中的个体差异。最近的研究集中于DNA甲基化对ADME基因表达和药物反应的重要性。其中，最研究的是抗肿瘤药物，其次是抗结核和抗血栓药物。因此，我们提供了一个表观遗传学的视角来解释药物反应的变异。这篇综述总结了ADME基因表达和DNA甲基化之间的相关性，包括确切的甲基化位置，并着重于相应的药物代谢和作用，以阐明临床用药中的个体差异。

Interindividual differences in drug response have always existed in clinical treatment. Genes involved in drug absorption, distribution, metabolism, and excretion (ADME) play an important role in the process of pharmacokinetics. The effects of genetic polymorphism and nuclear receptors on the expression of drug metabolism enzymes and transporters can only explain some individual differences in clinical treatment. Several key ADME genes have been demonstrated to be regulated by epigenetic mechanisms that can potentially affect inter-individual variability in medical treatment. Emerging studies have focused on the importance of DNA methylation for ADME gene expression and for drug response. Among them, the most studied are anti-tumor drugs, followed by anti-tuberculous and anti-platelet drugs. Therefore, we provide an epigenetics perspective on variability in drug response. The review summarizes the correlation between ADME gene expression and DNA methylation, including the exact methylation locations, and focuses on the corresponding drug disposition and effects to illuminate interindividual differences in clinical medication.